CSPC Pharmaceutical Group (01093.HK): CSPC Innovation's net profit attributable to shareholders for the first three quarters was RMB 1.21 billion.

Zhitong Finance APP News: CSPC Pharmaceutical Group (01093.HK) has issued an announcement that its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd. (CSPC Innovation), achieved operating revenue of RMB 3.976 billion in the first three quarters of 2026, a year-on-year increase of 149.62%; net profit attributable to shareholders of the listed company was RMB 1.21 billion; basic earnings per share were RMB 0.8688.